Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR

World Journal of Gastroenterology

Volumn 20, Issue 19, 2014, Pages 5897-5902

  Jamalidoust, Marzieh ^a,b   Namayandeh, Mandana ^a   Asaei, Sadaf ^a   Aliabadi, Nasrin ^a   Ziyaeyan, Mazyar ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Hepatitis C virus genotype distribution; Injection drug users; Iran; Real time PCR

Indexed keywords

ILLICIT DRUG;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DRUG ABUSE; FEMALE; GENE FREQUENCY; GENOTYPING TECHNIQUE; HEMOPHILIA; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; THALASSEMIA; ADOLESCENT; BLOOD; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; IRAN; MIDDLE AGED; PRISONER; SUBSTANCE ABUSE; TATTOOING; VIROLOGY; VIRUS GENE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; GENES, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; IRAN; MALE; MIDDLE AGED; PRISONERS; REAL-TIME POLYMERASE CHAIN REACTION; SUBSTANCE ABUSE, INTRAVENOUS; TATTOOING; YOUNG ADULT;

EID: 84901207720     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i19.5897     Document Type: Article

References (32)

1. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-573 [PMID: 19589081 DOI: 10.1086/600304]
2. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003; 7: 261-287 [PMID: 12691470 DOI: 10.1016/S1089-3261(02)00078-8]
3. Kamal S. Genotypic variations around the world: Is hepatitis C virus evolving? Curr Hepat Rep 2006; 5: 142-149
4. Ramia S, Melhem NM, Kreidieh K. Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population. Infection 2012; 40: 1-10 [PMID: 22237470 DOI: 10.1007/ s15010-011-0236-z]
5. Kassaian N, Adibi P, Kafashaian A, Yaran M, Nokhodian Z, Shoaei P, Hassannejad R, Babak A, Ataei B. Hepatitis C Virus and Associated Risk Factors among Prison Inmates with History of Drug Injection in Isfahan, Iran. Int J Prev Med 2012; 3: S156-S161 [PMID: 22826759]
6. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008; 46: 78-84 [PMID: 18171217 DOI: 10.1086/523585]
7. Nakatani SM, Santos CA, Riediger IN, Krieger MA, Duarte CA, Lacerda MA, Biondo AW, Carrilho FJ, Ono-Nita SK. Development of hepatitis C virus genotyping by real-time PCR based on the NS5B region. PLoS One 2010; 5: e10150 [PMID: 20405017 DOI: 10.1371/journal.pone.0010150]
8. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virol J 2011; 8: 161 [PMID: 21477382 DOI: 10.1186/1743-422X-8-161]
9. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18: 352-358 [PMID: 17854722 DOI: 10.1016/j.drugpo.2007.04.004]
10. Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S. Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon. Virol J 2010; 7: 96 [PMID: 20465784 DOI: 10.1186/1743-422X-7-96]
11. Hutchinson SJ, Roy KM, Wadd S, Bird SM, Taylor A, Anderson E, Shaw L, Codere G, Goldberg DJ. Hepatitis C virus infection in Scotland: epidemiological review and public health challenges. Scott Med J 2006; 51: 8-15 [PMID: 16722130 DOI: 10.1258/rsmsmj.51.2.8]
12. Cantaloube JF, Gallian P, Attoui H, Biagini P, De Micco P, de Lamballerie X. Genotype distribution and molecular epidemiology of hepatitis C virus in blood donors from southeast France. J Clin Microbiol 2005; 43: 3624-3629 [PMID: 16081888 DOI: 10.1128/JCM.43.8.3624-3629.2005]
13. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 1998; 352: 1426-1432 [PMID: 9807989 DOI: 10.1016/S0140-6736(98)07124-4]
14. Su TH, Liu CH, Liu CJ, Chen CL, Ting TT, Tseng TC, Chen PJ, Kao JH, Chen DS. Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proc Natl Acad Sci USA 2013; 110: 7844-7849 [PMID: 23613588 DOI: 10.1073/pnas.1306138110]
15. Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis--United States, 2006. MMWR Surveill Summ 2008; 57: 1-24 [PMID: 18354374]
16. Astone JM, Strauss SM, Hagan H, Des Jarlais DC. Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services. Am J Drug Alcohol Abuse 2004; 30: 783-797 [PMID: 15624549 DOI: 10.1081/ADA-200037544]
17. Kurelac I, Papic N, Sakoman S, Orban M, Dusek D, Coric M, Vince A. Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate: experience From Croatian Reference Center for Viral Hepatitis. Hepat Mon 2011; 11: 986-992 [PMID: 22368683 DOI: 10.5812/kowsar.1735143X.779]
18. Brunner N, Senn O, Rosemann T, Falcato L, Bruggmann P. Hepatitis C treatment for multimorbid patients with substance use disorder in a primary care-based integrated treatment centre: a retrospective analysis. Eur J Gastroenterol Hepatol 2013; 25: 1300-1307 [PMID: 23571610 DOI: 10.1097/ MEG.0b013e32836140bb]
19. Bojovic K, Simonovic J, Katanic N, Milosevic I, Pesic I, Delic D, Svirtlih N, Jevtovic DJ. The comparison of chronic hepatitis C treatment outcome between intravenous drug users and non-intravenous drug users. Biomed Pharmacother 2013; 67: 517-520 [PMID: 23639229 DOI: 10.1016/j.biopha.2013.03.010]
20. Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther 2013; 37: 921-936 [PMID: 23557103 DOI: 10.1111/apt.12300]
21. Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 2008; 47: 1371-1383 [PMID: 18240152 DOI: 10.1002/hep.22127]
22. Kamal SM. Improving outcome in patients with hepatitis C virus genotype 4. Am J Gastroenterol 2007; 102: 2582-2588 [PMID: 17900328 DOI: 10.1111/j.1572-0241.2007.01538.x]
23. Zhao L, Feng Y, Xia XS. [The different epidemic and evolution of HCV genotypes]. Yi Chuan 2012; 34: 666-672 [PMID: 22698736 DOI: 10.3724/SP.J.1005.2012.00666]
24. Waqar M, Khan AU, Rehman HU, Idrees M, Wasim M, Ali A, Niaz Z, Ismail Z, Rehman MU, Tariq M, Shah M, Murtaza BN. Determination of hepatitis C virus genotypes circulating in different districts of Punjab (Pakistan). Eur J Gastroenterol Hepatol 2014; 26: 59-64 [PMID: 23743560 DOI: 10.1097/ MEG.0b013e328362dc3f]
25. Butt S, Idrees M, Akbar H, ur Rehman I, Awan Z, Afzal S, Hussain A, Shahid M, Manzoor S, Rafique S. The changing epidemiology pattern and frequency distribution of hepatitis C virus in Pakistan. Infect Genet Evol 2010; 10: 595-600 [PMID: 20438863 DOI: 10.1016/j.meegid.2010.04.012]
26. Kabir A, Alavian SM, Keyvani H. Distribution of hepatitis C virus genotypes in patients infected by different sources and its correlation with clinical and virological parameters: a preliminary study. Comp Hepatol 2006; 5: 4 [PMID: 17014721 DOI: 10.1186/1476-5926-5-4]
27. Zarkesh-Esfahani SH, Kardi MT, Edalati M. Hepatitis C virus genotype frequency in Isfahan province of Iran: a descriptive cross-sectional study. Virol J 2010; 7: 69 [PMID: 20331907 DOI: 10.1186/1743-422X-7-69]
28. Vossughinia H, Goshayeshi L, Bayegi HR, Sima H, Kazemi A, Erfani S, Abedini S, Goshayeshi L, Ghaffarzadegan K, Nomani H, Jamehdar SA. Prevalence of Hepatitis C Virus Genotypes in Mashhad, Northeast Iran. Iran J Public Health 2012; 41: 56-61 [PMID: 23193507]
29. Farivar TN, Nezam MK, Johari P. Genotyping of hepatitis C virus isolated from hepatitis patients in Southeast of Iran by Taqman Realtime PCR. J Pak Med Assoc 2011; 61: 586-588 [PMID: 22204216]
30. Rafiei A, Darzyani AM, Taheri S, Haghshenas MR, Hosseinian A, Makhlough A. Genetic diversity of HCV among various high risk populations (IDAs, thalassemia, hemophilia, HD patients) in Iran. Asian Pac J Trop Med 2013; 6: 556-560 [PMID: 23768829 DOI: 10.1016/S1995-7645(13)60096-6]
31. Samimi-Rad K, Nasiri Toosi M, Masoudi-Nejad A, Najafi A, Rahimnia R, Asgari F, Shabestari AN, Hassanpour G, Alavian SM, Asgari F. Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. Arch Virol 2012; 157: 1959-1965 [PMID: 22695769 DOI: 10.1007/s00705-012-1369-9]
32. Ziyaeyan M, Alborzi A, Jamalidoust M, Badiee P, Moeini M, Kadivar A, Prevalence of hepatitis C virus genotypes in chronic infected patients, southern Iran. Jundishapur J Microbiol 2011; 4: 141-146